Scott J. Nicholson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Scott J. Nicholson has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Arturo Arrona-Palacios
Division of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA
1 shared publication - Charles A. Czeisler
Division of Sleep and Circadian Medicine, Department of Medicine, Mass General Brigham, Boston, USA
1 shared publication - Elizabeth B. Klerman
Department of Neurology, Mass General Brigham , Boston, Massachusetts
1 shared publication - Hilary A. Uyhelji
Federal Aviation Administration, Civil Aerospace Medical Institute, Oklahoma City, USA
1 shared publication - Joseph M. Ronda
Division of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women’s Hospital, Mass General Brigham, Boston, USA
1 shared publication - Julia L. O. Beckel
Department of Psychology, Colorado State University, Fort Collins, USA
1 shared publication
Latest Publications
- Open Access
- 14 November 2025
- Published by Springer Nature in BMC Genomics
- Vol. 26 (1) , 1043
Exploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation
Background: Inter-individual variation in response to insufficient or altered timing of sleep presents a challenge for the development of personalized approaches to fatigue monitoring and mitigation. Insufficient sleep has adverse health impacts, can result in impaired neurobehavioral performance, and can substantially increase the risk of injury and even mortality in safety–critical operations such as transportation. The present study provides a detailed exploration of physiological, neurobehavioral, and gene expression changes during sleep restriction, acute total sleep deprivation, and altered timing of sleep among 59 healthy volunteer participants who completed a 10-day inpatient study. Results: Reducing the quantity or altering the timing of sleep significantly impacts self-reported estimates of sleep duration, polysomnography-recorded sleep stages, and neurobehavioral performance test results. Impaired neurobehavioral performance was associated with transcriptomic changes in gene expression. A comparison of current and prior research on total sleep deprivation indicated that reproducible candidate gene expression biomarkers exist for at least one metric of attention, specifically, Psychomotor Vigilance Test (PVT) lapses. Conclusions: Candidate biomarkers of fatigue-related impairment were identified that responded to single neurobehavioral performance endpoints, as well as those that responded to multiple types or metrics of performance. Reproducible identification of biomarker candidates for PVT lapses during total sleep deprivation increases confidence in the ability to develop a molecular approach to fatigue-related impairment detection, while novel discoveries expanded the list of candidate genes to other impairment metrics. Molecular biomarkers for neurobehavioral performance impairment represent a potentially valuable tool to more precisely monitor the neurobehavioral performance deficits resulting from sleep loss, and further research and validation could eventually augment fatigue risk management practices that historically emphasize scheduling and rest opportunities. The data generated from self-assessment, polysomnography, neurobehavioral performance, and molecular investigations provide a wealth of information made publicly available for further data mining and scientific advancements. Trial registration: ClinicalTrials.gov, TRN: NCT04211506, Registered 23 December 2019.
- 14 November 2025
- Published by Springer Nature in BMC Genomics
- Vol. 26 (1) , 1043
Open AccessExploratory development of biomarkers for neurobehavioral performance impairment during sleep loss: comparison across multiple types of sleep deprivation
Background: Inter-individual variation in response to insufficient or altered timing of sleep presents a challenge for the development of personalized approaches to fatigue monitoring and mitigation. Insufficient sleep has adverse health impacts, can result in impaired neurobehavioral performance, and can substantially increase the risk of injury and even mortality in safety–critical operations such as transportation. The present study provides a detailed exploration of physiological, neurobehavioral, and gene expression changes during sleep restriction, acute total sleep deprivation, and altered timing of sleep among 59 healthy volunteer participants who completed a 10-day inpatient study. Results: Reducing the quantity or altering the timing of sleep significantly impacts self-reported estimates of sleep duration, polysomnography-recorded sleep stages, and neurobehavioral performance test results. Impaired neurobehavioral performance was associated with transcriptomic changes in gene expression. A comparison of current and prior research on total sleep deprivation indicated that reproducible candidate gene expression biomarkers exist for at least one metric of attention, specifically, Psychomotor Vigilance Test (PVT) lapses. Conclusions: Candidate biomarkers of fatigue-related impairment were identified that responded to single neurobehavioral performance endpoints, as well as those that responded to multiple types or metrics of performance. Reproducible identification of biomarker candidates for PVT lapses during total sleep deprivation increases confidence in the ability to develop a molecular approach to fatigue-related impairment detection, while novel discoveries expanded the list of candidate genes to other impairment metrics. Molecular biomarkers for neurobehavioral performance impairment represent a potentially valuable tool to more precisely monitor the neurobehavioral performance deficits resulting from sleep loss, and further research and validation could eventually augment fatigue risk management practices that historically emphasize scheduling and rest opportunities. The data generated from self-assessment, polysomnography, neurobehavioral performance, and molecular investigations provide a wealth of information made publicly available for further data mining and scientific advancements. Trial registration: ClinicalTrials.gov, TRN: NCT04211506, Registered 23 December 2019.